rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-2-226-232rpcardio-563Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИCURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2СОВРЕМЕННЫЕ МИШЕНИ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ. ДАННЫЕ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ ЧАСТЬ 2ПоповВ. В.PopovV. V.

д.м.н., зав. лабораторией профессиональной клинической фармакологии 

vpopov@css-rzd.ruБулановаН. А.BulanovN. A.

к.м.н., в.н.с. отдела кардиологии 

ИвановГ. Г.IvanovG. G.

д.м.н., профессор, заведующий отделом кардиологии 

Научный клинический центр ОАО «Российские железные дороги»РоссияResearch Clinical Center of JSC "Russian Railways"Russian FederationПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Setchenov First Moscow State Medical UniversityRussian Federation20120301201682226232Copyright © Popov V.V., Bulanov N.A., Ivanov G.G., 20152015Попов В.В., Буланова Н.А., Иванов Г.Г.Popov V.V., Bulanov N.A., Ivanov G.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/563

Arterial hypertension (HT) takes leading position in the structure of morbidity and mortality among the cardiovascular diseases in the economically developed and developing countries of the world. Despite progress in treatment of this disease, a number of people with uncontrolled or resistant HT increases. There is a problem of inefficiency of therapy or lack of patients' adherence to treatment. Therefore, search for new approaches to treatment of HT continues. Current most effective agents for blood pressure control, and possible future antihypertensive agents, are related to groups of agents, which inhibit renin–angiotensin–aldosterone system (RAAS). Novel targets for antihypertensive therapy could include the angiotensin II type 2 and type 1 receptor , neutral endopeptidase, aldosterone synthase, renalase, endothelin receptors, (pro)renin receptors, vaccine against RAAS components. Development of novel agents and approaches to HT therapy is discussed.

Артериальная гипертензия (АГ) занимает лидирующую позицию в структуре заболеваемости и смертности от сердечно-сосудистых заболеваний в экономически развитых и развивающихся странах мира. Несмотря на прогресс в лечении данного заболевания, количество пациентов с неконтролируемой и резистентной формой АГ растёт. Остаются крайне актуальными проблемы неэффективности фармакотерапии и недостаточной приверженности пациентов лечению. В связи с этим продолжаются поиски новых препаратов и подходов к лечению АГ . Самые эффективные на сегодняшний день и, возможно, в будущем — лекарственные препараты, относящиеся к классу веществ, которые ингибируют ренин-ангиотензин-альдостероновую систему (РААС). Новыми мишенями для гипотензивной терапии являются ангиотензиновые рецепторы 1-ого и 2-ого типов, нейтральная эндопептидаза, альдостерон-синтаза, реналаза, эндотелиновые рецепторы, (про)рениновые рецепторы, вакцины против компонентов РААС. Данная статья посвящена новым средствам и подходам к антигипертензивной терапии.

артериальная гипертензиягипотензивные препаратыфармакологические мишениклинические исследованияarterial hypertensionantihypertensive drugspharmacological targetsclinical trialsReferencesPopov V.V., Bulanov N.A., Ivanov G.G. Current target of antihypertensive therapy. Data from clinical trials. Part 1. Rational Pharmacother Card 2012; 8(1):88–94. Russian (Попов В.В., Буланова Н.А., Иванов Г .Г . Современные мишени антигипертензивной терапии. Данные клинических исследований. Часть 1. РФК 2012; 8(1): 88–94).Popov V.V., Bulanov N.A., Ivanov G.G. Current target of antihypertensive therapy. Data from clinical trials. Part 1. Rational Pharmacother Card 2012; 8(1):88–94. Russian (Попов В.В., Буланова Н.А., Иванов Г .Г . Современные мишени антигипертензивной терапии. Данные клинических исследований. Часть 1. РФК 2012; 8(1): 88–94).Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010; 7: 431–41.Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010; 7: 431–41.Tabrizchi R. Ilepatril (AVE–7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs 2008; 9(3): 301–9.Tabrizchi R. Ilepatril (AVE–7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs 2008; 9(3): 301–9.Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 10(375): 1255–66.Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010; 10(375): 1255–66.Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005; 39(9): 1401–1408.Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005; 39(9): 1401–1408.Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (London) 2004; 107: 167–173.Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (London) 2004; 107: 167–173.Ambühl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: pre- clinical efficacy and Phase I safety and immunogenicity. J Hypertens 2007; 25: 63–72.Ambühl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: pre- clinical efficacy and Phase I safety and immunogenicity. J Hypertens 2007; 25: 63–72.Tissot AC, Maurer P , Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006- AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821–827.Tissot AC, Maurer P , Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006- AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821–827.Pandey R, Quan WY , Hong F , Jie SL. Vaccine for hypertension: Modulating the renin-angiotensin system. International Journal of Cardiology 2009; 134(2): 160–168.Pandey R, Quan WY , Hong F , Jie SL. Vaccine for hypertension: Modulating the renin-angiotensin system. International Journal of Cardiology 2009; 134(2): 160–168.Maurer P ., Bachmann M. Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010; 134 (1): 89–95.Maurer P ., Bachmann M. Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010; 134 (1): 89–95.Samuelsson O., Herlitz H. Vaccination against high blood pressure: a new strategy. Lancet 2008; 371: 788.Samuelsson O., Herlitz H. Vaccination against high blood pressure: a new strategy. Lancet 2008; 371: 788.Staessen JA, Bulpitt CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: 427–33.Staessen JA, Bulpitt CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: 427–33.Zanchetti A, Facchetti R, Cesana G, et al. Menopause-related blood pressure increase and its relationship to age and body mass index: SIMONA epidemiological study. J Hypertens 2005; 23: 2269–76.Zanchetti A, Facchetti R, Cesana G, et al. Menopause-related blood pressure increase and its relationship to age and body mass index: SIMONA epidemiological study. J Hypertens 2005; 23: 2269–76.Баранова Е.И. Артериальная гипертензия в постменопаузе: патогенез и подходы к терапии. Фарматека 2009; 12: 29–34.Баранова Е.И. Артериальная гипертензия в постменопаузе: патогенез и подходы к терапии. Фарматека 2009; 12: 29–34.Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299(9): 1036–1045.Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299(9): 1036–1045.Drospirenone in HRT? Drug Ther Bull 2009; 47(4): 41–44.Drospirenone in HRT? Drug Ther Bull 2009; 47(4): 41–44.Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenopausal women with hypertension. Drugs Aging 2007; 24(6): 453–66.Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenopausal women with hypertension. Drugs Aging 2007; 24(6): 453–66.White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy , drospirenone and 17- beta-estradiol in postmenopausal women with hypertension. Hypertension 2006; 48(2): 246– 253.White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy , drospirenone and 17- beta-estradiol in postmenopausal women with hypertension. Hypertension 2006; 48(2): 246– 253.Xu J, Li G, Wang P , Velazquez H, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115: 1275–1280.Xu J, Li G, Wang P , Velazquez H, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115: 1275–1280.Li G, Xu J, Wang P , et al. Catecholamines regulate the activity , secretion, and synthesis of renalase. Circulation 2008; 117: 1277–1282.Li G, Xu J, Wang P , et al. Catecholamines regulate the activity , secretion, and synthesis of renalase. Circulation 2008; 117: 1277–1282.Desir G. V. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int 2009; 76: 366–370.Desir G. V. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int 2009; 76: 366–370.Ruiz-Hurtado G, Fernández-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor , prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007; 50: 1049–1056.Ruiz-Hurtado G, Fernández-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor , prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007; 50: 1049–1056.Stasch JP , Dembowsky K, Perzborn E, et al. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator , BAY 41–8543: in vivo studies. Br J Pharmacol 2002; 135: 344–355.Stasch JP , Dembowsky K, Perzborn E, et al. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator , BAY 41–8543: in vivo studies. Br J Pharmacol 2002; 135: 344–355.Zanfolin M, Faro R, Araujo EG, et al. Protective effects of BAY 41–2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAMe treatment in rats. J Cardiovasc Pharmacol 2006; 47: 391–395.Zanfolin M, Faro R, Araujo EG, et al. Protective effects of BAY 41–2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAMe treatment in rats. J Cardiovasc Pharmacol 2006; 47: 391–395.Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58–2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009; 119: 2781–2788.Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58–2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009; 119: 2781–2788.Chen D, Whitcomb R, Macintyre E, et al Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects. J Clin Pharmacol 2012;52(3):319–28.Chen D, Whitcomb R, Macintyre E, et al Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects. J Clin Pharmacol 2012;52(3):319–28.Baerwald C, Verdecchia P , Duquesroix B, et al. Efficacy , safety , and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010; 62: 3635–3644.Baerwald C, Verdecchia P , Duquesroix B, et al. Efficacy , safety , and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010; 62: 3635–3644.Galiè N, Brundage BH, Ghofrani HA, et al. for the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.Galiè N, Brundage BH, Ghofrani HA, et al. for the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.Sawamura F , Kato M, Fujita K, et al. Tadalafil, a long-acting inhibitor of PDe5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci 2009; 111: 235–243.Sawamura F , Kato M, Fujita K, et al. Tadalafil, a long-acting inhibitor of PDe5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci 2009; 111: 235–243.Hsu S, Nagayama T, Koitabashi N, et al. Phosphodiesterase 5 inhibition blocks pressure overload- induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009; 81: 301–309.Hsu S, Nagayama T, Koitabashi N, et al. Phosphodiesterase 5 inhibition blocks pressure overload- induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009; 81: 301–309.Bednar M. M. The role of sildenafil in the treatment of stroke. Curr Opin Investig 2008; 9: 754– 759.Bednar M. M. The role of sildenafil in the treatment of stroke. Curr Opin Investig 2008; 9: 754– 759.Zaslavskaya R.M., Shakirova A.N. Melatonin (melaxen) in the treatment of hypertension. Praktikuyushchiy Vrach 2006; 1: 10–16. Russian (Заславская Р .М., Шакирова А.Н. Мелатонин (Мелаксен) в лечении артериальной гипертонии. Практикующий Врач 2006; 1: 10 –16).Zaslavskaya R.M., Shakirova A.N. Melatonin (melaxen) in the treatment of hypertension. Praktikuyushchiy Vrach 2006; 1: 10–16. Russian (Заславская Р .М., Шакирова А.Н. Мелатонин (Мелаксен) в лечении артериальной гипертонии. Практикующий Врач 2006; 1: 10 –16).Zaslavskaya R.M., Lilitsa G.V., Shcherban' E.A. Melatonin (melaxen) in treatment of coronary heart disease. Praktikuyushchiy Vrach 2006; 2: 14–19. Russian (Заславская Р .М., Лилица Г .В., Щербань Э.А. Мелатонин (мелаксен) в комплексном лечении ишемической болезни сердца. Практикующий Врач 2006; 2: 14–19).Zaslavskaya R.M., Lilitsa G.V., Shcherban' E.A. Melatonin (melaxen) in treatment of coronary heart disease. Praktikuyushchiy Vrach 2006; 2: 14–19. Russian (Заславская Р .М., Лилица Г .В., Щербань Э.А. Мелатонин (мелаксен) в комплексном лечении ишемической болезни сердца. Практикующий Врач 2006; 2: 14–19).Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16–25.Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16–25.Paulis L., Simko F . Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56: 671–684.Paulis L., Simko F . Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56: 671–684.Тимофеева А.В., Г орюнова Л.Е. и др. Фармакогенетика, фармакогеномика в свете проблем, связанных с эссенциальной артериальной гипертонией. Consilium Medicum. Кардиологический вестник 2007; 2(1): 5–12.Тимофеева А.В., Г орюнова Л.Е. и др. Фармакогенетика, фармакогеномика в свете проблем, связанных с эссенциальной артериальной гипертонией. Consilium Medicum. Кардиологический вестник 2007; 2(1): 5–12.Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin- converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111: 3374–3383.Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin- converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111: 3374–3383.

The authors declare that there are no conflicts of interest present.